Literature DB >> 21376021

Disruption of downstream MyD88 or TRIF Toll-like receptor signaling does not protect against cerebral ischemia.

Bolanle M Famakin1, Yongshan Mou, Christl A Ruetzler, Joliet Bembry, Dragan Maric, John M Hallenbeck.   

Abstract

Toll-like receptor (TLR) signaling plays an important role in cerebral ischemia, but downstream signaling events, which can be organ-specific, are incompletely understood. We thereby investigated involvement of the MyD88-dependent (MyD88) and MyD88-independent (TRIF) TLR signaling pathways in 2 in vitro and 2 in vivo models of cerebral ischemia. For in vitro studies, we used a model of oxygen-glucose deprivation (OGD) followed by flow cytometric analysis to determine:1) viability of PC12 cells following knock-down with MyD88 siRNA compared to negative control siRNA and 2) viability, apoptosis and necrosis of cortical neurons from MyD88 null (-/-) , TRIF mutant, and wild type (WT) mice. In addition, in vivo, 1) We examined CA1 neuronal survival 7 days after global forebrain ischemia and 2) infarct volumes 24h after Middle Cerebral Artery Occlusion (MCAO) in all 3 types of mice. OGD: 1) There were no differences in either percent viability of PC12 cells transfected with MyD88 compared to negative control siRNA or 2) in percent viability, apoptosis and necrosis of cortical neurons from MyD88-/-,TRIF mutant and WT mice. Global ischemia: neuronal survival was similar in all 3 groups of mice. Finally, MCAO: infarct volumes were not statistically different among all 3 groups of mice: MyD88-/-, 23.9±9.9 mm(3), TRIF mutant, 26.7±5.8 mm(3) and WT, 17.9±8.4mm(3). These findings show that disruption of MyD88 or TRIF signaling does not confer protection in brain ischemia and suggests the possibility of additional or alternate downstream adaptors during TLR signaling in cerebral ischemia. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376021      PMCID: PMC3126100          DOI: 10.1016/j.brainres.2011.02.074

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  24 in total

1.  The transcription factor interferon regulatory factor-1 mediates liver damage during ischemia-reperfusion injury.

Authors:  Allan Tsung; Michael T Stang; Atsushi Ikeda; Nathan D Critchlow; Kunihiko Izuishi; Atsunori Nakao; Meagan H Chan; Geetha Jeyabalan; John H Yim; David A Geller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-01-12       Impact factor: 4.052

2.  Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts.

Authors:  Fang Hua; Tuanzhu Ha; Jing Ma; Xiang Gao; Jim Kelley; David L Williams; I William Browder; Race L Kao; Chuanfu Li
Journal:  Biochem Biophys Res Commun       Date:  2005-10-21       Impact factor: 3.575

3.  Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke.

Authors:  Javier R Caso; Jesús M Pradillo; Olivia Hurtado; Pedro Lorenzo; María A Moro; Ignacio Lizasoain
Journal:  Circulation       Date:  2007-03-19       Impact factor: 29.690

4.  Development of an ischemic tolerance model in a PC12 cell line.

Authors:  Joëlle A Hillion; Kenzo Takahashi; Dragan Maric; Christl Ruetzler; Jeffery L Barker; John M Hallenbeck
Journal:  J Cereb Blood Flow Metab       Date:  2005-02       Impact factor: 6.200

5.  TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways.

Authors:  Alana A Shigeoka; Todd D Holscher; Andrew J King; Frank W Hall; William B Kiosses; Peter S Tobias; Nigel Mackman; Dianne B McKay
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

6.  Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function.

Authors:  O Adachi; T Kawai; K Takeda; M Matsumoto; H Tsutsui; M Sakagami; K Nakanishi; S Akira
Journal:  Immunity       Date:  1998-07       Impact factor: 31.745

7.  Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion.

Authors:  Fang Hua; Jing Ma; Tuanzhu Ha; Yeling Xia; Jim Kelley; David L Williams; Race L Kao; I William Browder; John B Schweitzer; John H Kalbfleisch; Chuanfu Li
Journal:  J Neuroimmunol       Date:  2007-09-19       Impact factor: 3.478

8.  Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits.

Authors:  Sung-Chun Tang; Thiruma V Arumugam; Xiangru Xu; Aiwu Cheng; Mohamed R Mughal; Dong Gyu Jo; Justin D Lathia; Dominic A Siler; Srinivasulu Chigurupati; Xin Ouyang; Tim Magnus; Simonetta Camandola; Mark P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-10       Impact factor: 11.205

9.  TLR2 has a detrimental role in mouse transient focal cerebral ischemia.

Authors:  Gina Ziegler; Denise Harhausen; Claudia Schepers; Olaf Hoffmann; Christina Röhr; Vincent Prinz; Janett König; Hans Lehrach; Wilfried Nietfeld; George Trendelenburg
Journal:  Biochem Biophys Res Commun       Date:  2007-05-30       Impact factor: 3.575

10.  MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival.

Authors:  Younghwa Kim; Ping Zhou; Liping Qian; Jen-Zen Chuang; Jessica Lee; Chenjian Li; Costantino Iadecola; Carl Nathan; Aihao Ding
Journal:  J Exp Med       Date:  2007-08-27       Impact factor: 14.307

View more
  20 in total

Review 1.  Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential.

Authors:  Mark L Hanke; Tammy Kielian
Journal:  Clin Sci (Lond)       Date:  2011-11       Impact factor: 6.124

Review 2.  The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review.

Authors:  Bolanle M Famakin
Journal:  Aging Dis       Date:  2014-10-01       Impact factor: 6.745

3.  Genipin attenuates sepsis by inhibiting Toll-like receptor signaling.

Authors:  Tae-Hoon Kim; Seong-Jin Yoon; Sun-Mee Lee
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

4.  Toll-like receptor-3 activation increases the vulnerability of the neonatal brain to hypoxia-ischemia.

Authors:  Linnea Stridh; Amin Mottahedin; Maria E Johansson; Raul Chavez Valdez; Frances Northington; Xiaoyang Wang; Carina Mallard
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

5.  A new role for downstream Toll-like receptor signaling in mediating immediate early gene expression during focal cerebral ischemia.

Authors:  Bolanle M Famakin; Yongshan Mou; Kory Johnson; Maria Spatz; John Hallenbeck
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-04       Impact factor: 6.200

6.  Discovery of Intermediary Genes between Pathways Using Sparse Regression.

Authors:  Kuo-ching Liang; Ashwini Patil; Kenta Nakai
Journal:  PLoS One       Date:  2015-09-08       Impact factor: 3.240

7.  Post-ischemic inflammation in the brain.

Authors:  Takashi Shichita; Ryota Sakaguchi; Mayu Suzuki; Akihiko Yoshimura
Journal:  Front Immunol       Date:  2012-05-31       Impact factor: 7.561

8.  Downstream Toll-like receptor signaling mediates adaptor-specific cytokine expression following focal cerebral ischemia.

Authors:  Bolanle Famakin; Yongshan Mou; Maria Spatz; Modinat Lawal; John Hallenbeck
Journal:  J Neuroinflammation       Date:  2012-07-16       Impact factor: 8.322

9.  Pharmacological inhibition of TLR4-NOX4 signal protects against neuronal death in transient focal ischemia.

Authors:  Yukiya Suzuki; Kozo Hattori; Junya Hamanaka; Tetsuji Murase; Yusuke Egashira; Keisuke Mishiro; Mitsunori Ishiguro; Kazuhiro Tsuruma; Yoshinobu Hirose; Hiroyuki Tanaka; Shinichi Yoshimura; Masamitsu Shimazawa; Naoki Inagaki; Hideko Nagasawa; Toru Iwama; Hideaki Hara
Journal:  Sci Rep       Date:  2012-11-28       Impact factor: 4.379

10.  MyD88 is a critical regulator of hematopoietic cell-mediated neuroprotection seen after stroke.

Authors:  Catherine E Downes; Connie H Y Wong; Katya J Henley; Pedro L Guio-Aguilar; Moses Zhang; Robert Ates; Ashley Mansell; Benjamin T Kile; Peter J Crack
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.